Close menu




BIONTECH SE SPON. ADRS 1

Photo credits: pixabay.com

Commented by Armin Schulz on May 14th, 2025 | 07:00 CEST

Patents, partnerships & tumor strategies: How Novo Nordisk, BioNxt Solutions, and BioNTech are securing tomorrow's profits

  • Biotechnology
  • Biotech
  • Pharma

The global pharmaceutical industry, once the epitome of stable investments, is undergoing radical change. While protectionist trade barriers are disrupting supply chains and causing stock market prices to plummet, companies are forecasting growth for the biotech and pharmaceutical industries, according to the industry study "Life Sciences Executives Flash Report." The crisis is turning out to be a laboratory of opportunities – those who prioritize digital therapies, mRNA technologies, or sustainable production models now could emerge as winners in a reorganized market. But which strategies are convincing? We take a closer look at Novo Nordisk, BioNxt Solutions, and BioNTech.

Read

Commented by Nico Popp on May 13th, 2025 | 07:10 CEST

The fight against cancer as a billion-dollar opportunity: BioNTech, Merck, and Vidac Pharma

  • Biotechnology
  • Biotech
  • Pharma

Cancer is the scourge of our time. However, significant progress has already been made in recent years. In addition to significantly improved traditional therapies, individualized treatment approaches such as immunotherapy are repeatedly proving successful in curing patients. This trend is set to continue. Experts such as the investors at Candriam and market researchers at Spherical Insights foresee enormous growth – the market for cancer drugs could see double-digit annual growth by the 2030s. Market leaders such as BioNTech and Merck, as well as insider tips like Vidac Pharma, stand to benefit.

Read

Commented by Nico Popp on May 8th, 2025 | 07:00 CEST

Data as a return booster: NetraMark, BioNTech, and Palantir Technologies

  • AI
  • Biotechnology
  • Biotech
  • Software

It is common knowledge by now that data is the raw material of the 21st century. However, only a few truly understand the many ways in which this digital raw material can now be processed. Today, we present three companies - NetraMark, BioNTech, and Palantir Technologies - whose business models stand to benefit significantly from modern data processing and AI. We also examine whether there is any potential for collaboration between these companies.

Read

Commented by André Will-Laudien on May 5th, 2025 | 07:20 CEST

Biotech is back with artificial intelligence! Evotec, NetraMark Holdings, Bayer, and BioNTech

  • Biotechnology
  • Biotech
  • Pharma

Artificial intelligence has arrived in health research! Whenever large volumes of data need to be analyzed, patterns recognized, or results condensed, immense computing power is required. The goal is to detect complex structures, automate processes, and make real-time decisions. The use of AI in medicine and pharmaceutical development is making good progress because time and high validation capability are key here. Some companies have already recognized the signs of the times and are working hard on the new technologies. On the stock market, this is often the starting signal for significantly higher valuations. Evotec, Bayer, and BioNTech are well-known European players, while Canadian company NetraMark Holdings has seen its share price increase sevenfold since fall 2024. What is behind this surge?

Read

Commented by Fabian Lorenz on April 30th, 2025 | 07:15 CEST

Buy BioNTech after the crash? Valneva with vaccine problems! Vidac Pharma shares show potential!

  • Biotechnology
  • Biotech
  • Pharma

BioNTech shares crashed by around 10% on Friday. So far, they have not been able to recover. What caused the setback? Should investors seize the opportunity? Analysts believe the German biotech heavyweight is on track. The same applies to Vidac Pharma. The news flow is extremely positive, but the stock is not making any headway. Analysts believe that Vidac shares could multiply in value. If the biotech company continues to be successful, a takeover could follow. And what is going on at Valneva? The stock is on a rollercoaster ride. Could a vaccine become a problem?

Read

Commented by Stefan Feulner on April 28th, 2025 | 11:20 CEST

BioNTech, BioNxt, Merck KGaA – Opportunities after the correction

  • Biotechnology
  • Biotech
  • Technology

The reporting season for the first quarter of 2025 is underway, and due to US President Donald Trump's tariff hammer, it is more exciting than ever. Investors are likely to focus primarily on forecasts for the rest of the fiscal year. Internet giant Google posted impressive figures last week and is standing firm against looming trade conflicts and antitrust proceedings. Several companies in the biotech sector also had news to report and offer attractive entry opportunities at reduced prices.

Read

Commented by Nico Popp on April 25th, 2025 | 07:20 CEST

US biotechs under pressure – Where opportunities now lie: BioNTech, Pfizer, and Vidac Pharma

  • Biotechnology
  • Biotech
  • Pharma

The biotech world is in turmoil. The dispute between US President Donald Trump and the elite Harvard University is just the tip of the iceberg – thousands of researchers in the US are upset about the interference in their academic freedom. Research funding is being cut because of supposedly incorrect wording in applications. Entire degree programs are being put on hold because they do not fit into the worldview of the new US administration. The National Security Commission on Emerging Biotechnology (NSCEB) is warning of dire consequences for the US economy. Is the United States losing its status as a biotech mecca?

Read

Commented by Nico Popp on April 15th, 2025 | 09:50 CEST

Bayer, BioNTech, Defence Therapeutics: The new biotech reality opens up opportunities

  • Biotechnology
  • Biotech
  • Pharma

The pharmaceutical sector is exempt from US tariffs. But does that mean everything will be okay for the industry? During the German Biotech Days in Heidelberg, which took place last week, market experts were cautious. Following the layoffs at the US Food and Drug Administration (FDA), there are concerns among pharmaceutical companies and biotech firms that the US could lose its leading position in research and development. According to the researchers at the conference, Europe could step into the breach under certain conditions – however, partnerships with other regions remain crucial for continued progress.

Read

Commented by Fabian Lorenz on April 10th, 2025 | 07:30 CEST

A buying opportunity in the price horror? Novo Nordisk, BioNTech, and Defence Therapeutics!

  • Biotechnology
  • Biotech
  • Pharma

For Novo Nordisk shareholders, who have been spoiled by price gains, the current nightmare shows no sign of ending. The notion that pharmaceutical stocks are a safe haven in turbulent times is only partially true at the moment. Novo Nordisk shares are trading at their lowest level since 2022. A buying opportunity? Yes, analysts believe, but the Trump-induced chaos is not going away anytime soon. For those looking to invest in relative strength, there is currently no getting around Defence Therapeutics. The biotech company is not affected by tariff disputes and is taking big steps towards monetization. Yesterday, there was a strong price jump. Is a takeover coming soon? For example, BioNTech has full coffers and, as the latest IPO shows, is keen to invest in companies in the oncology sector.

Read

Commented by Armin Schulz on April 9th, 2025 | 07:00 CEST

From diabetes to cancer: How Novo Nordisk, NetraMark, and BioNTech are reinventing medicine

  • Biotechnology
  • Biotech
  • Pharma

The medicine of tomorrow is being written today – with algorithms that personalize therapies, mRNA vaccines that fight cancer, and drugs that conquer chronic diseases. While AI is revolutionizing clinical trials and shifting billion-dollar markets, biotech pioneers are fighting for dominance in precision medicine. Who is driving this transformation? Three companies are in the spotlight: Novo Nordisk, a pioneer in the fight against diabetes and obesity; NetraMark, whose AI is decoding clinical trials; and BioNTech, which is redefining oncology with mRNA. Their innovations are not just dreams of the future – they are already changing how lives are saved and extended.

Read